Fate Therapeutics (FATE) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress
May 10, 2018 4:01 PM EDTNo Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune
Anti-tumor Activity with No Dose-limiting Toxicities Observed in Initial Phase 1 Dose Escalation of FATE-NK100 in Advanced Solid and Liquid Tumors
IND for Off-the-Shelf NK Cell Product FT500 Remains on Track for 2Q18 Submission
Off-the-Shelf Dual-targeted CAR T-cell Product Demonstrates CD19 and CD20 Anti-tumor Activity in Preclinical Studies of Antigen Escape
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the... More
